#1 Clinical Trials Search in Europe

Thymalfasin

Thymalfasin, also known as thymosin alpha 1, is a synthetic peptide being investigated in clinical trials for its potential therapeutic effects in various medical conditions. This article summarizes key findings from recent clinical trials exploring the use of thymalfasin in diseases such as COVID-19, cancer, HIV, and sepsis. The trials aim to evaluate thymalfasin’s ability to modulate the immune system and potentially improve patient outcomes across different disease states.

Table of Contents

What is Thymalfasin?

Thymalfasin, also known as thymosin alpha 1 or Ta1, is a synthetic version of a naturally occurring compound in the body. It is the active ingredient in a medication called ZADAXIN[1]. Thymalfasin is a 28-amino acid peptide, which means it’s a small protein-like molecule that plays a role in regulating the immune system[1].

This medication has several other names you might encounter:

  • Thymosin alpha 1
  • Ta1
  • ZADAXIN

How Does Thymalfasin Work?

Thymalfasin is known as a biological response modifier. This means it can activate various cells of the immune system[1]. Specifically, it works by:

  • Enhancing the function of T helper cells (a type of white blood cell)
  • Increasing natural killer (NK) cell activity (another type of immune cell)
  • Improving antibody responses to antigens (substances that trigger an immune response)
  • Increasing the production of regulatory T cells, which help control inflammation[2]

By boosting these various aspects of the immune system, thymalfasin can help the body fight off infections and potentially combat certain types of cancer[1].

Conditions Treated with Thymalfasin

Thymalfasin has been studied for use in several medical conditions where the immune system is impaired or needs a boost. These include:

  • COVID-19: Studies are looking at whether thymalfasin can help prevent or treat COVID-19 infections, especially in high-risk patients like those with kidney disease[1][2].
  • HIV/AIDS: Thymalfasin is being investigated as a potential treatment to boost immune function in HIV-positive patients[3].
  • Cancer: Several studies are exploring the use of thymalfasin in various types of cancer, including:
    • Small cell lung cancer[4]
    • Non-small cell lung cancer[5]
    • Colorectal cancer[6][7]
  • Sepsis: This is a life-threatening condition caused by the body’s extreme response to an infection. Researchers are studying whether thymalfasin can help improve outcomes in patients with sepsis[8][9].
  • Hepatitis B: Thymalfasin is approved in some countries for the treatment of chronic hepatitis B[3].

How is Thymalfasin Administered?

Thymalfasin is typically given as a subcutaneous injection, which means it’s injected just under the skin. The dosage and frequency can vary depending on the condition being treated, but some common regimens include:

  • 1.6 mg twice weekly[1]
  • 1.6 mg daily for the first two weeks, then twice weekly[2]
  • 1.6 mg twice a week for 6 months (in some cancer studies)[7]

The medication usually comes as a powder that needs to be mixed with a liquid (reconstituted) before injection[8].

Current Clinical Trials

Thymalfasin is currently being studied in several clinical trials for various conditions. Some of these include:

  • Prevention of COVID-19 in dialysis patients[1]
  • Treatment of COVID-19 in patients with low lymphocyte counts[2]
  • Improving immune function in HIV-positive patients[3]
  • Combination with radiation therapy for metastatic cancers[4][5][6]
  • Adjuvant treatment after surgery for colorectal cancer[7]
  • Treatment of sepsis[8][9]

Potential Side Effects

Based on the information from clinical trials, thymalfasin appears to be generally well-tolerated. However, like all medications, it can cause side effects. Some potential side effects include:

  • Injection site reactions (pain, burning, itching)[2]
  • Fever
  • Nausea
  • Flu-like symptoms

These side effects are usually mild to moderate in severity[2]. However, it’s important to note that as thymalfasin is still being studied for many conditions, not all potential side effects may be known. Always discuss potential risks and benefits with your healthcare provider.

Condition Trial Design Key Outcomes Measured Thymalfasin Dosing
COVID-19 Randomized, placebo-controlled Infection rates, hospitalization, ICU admission, mechanical ventilation, recovery time 1.6 mg SC twice weekly for 8 weeks
Metastatic Cancer (various types) Single-arm, open-label Abscopal effect, tumor response, overall survival 1.6 mg SC twice weekly during radiotherapy
HIV with Immune Reconstitution Disorder Single-arm, prospective cohort CD4+ T cell counts, CD4/CD8 ratio, viral load 1.6 mg SC daily for 2 weeks, then twice weekly for 22 weeks
Sepsis Randomized, double-blind, placebo-controlled 28-day mortality, organ dysfunction scores, immune function markers 1.6 mg SC twice daily for up to 7 days

FAQ

  • What is thymalfasin and how does it work? Thymalfasin is a synthetic 28-amino acid peptide identical to natural thymosin alpha 1 produced by the thymus gland. It acts as a biological response modifier that activates various cells of the immune system, potentially providing benefits in conditions where immune responses are impaired or ineffective.
  • What conditions is thymalfasin being studied for in clinical trials? Clinical trials are investigating thymalfasin for a range of conditions including COVID-19, various types of cancer (small cell lung cancer, non-small cell lung cancer, colorectal cancer), HIV infection, and sepsis.
  • How is thymalfasin typically administered in these trials? In most trials, thymalfasin is administered via subcutaneous injection. Common dosing regimens include 1.6 mg given twice weekly or daily, with treatment durations ranging from 1-8 weeks depending on the specific trial and condition being studied.
  • What are some potential benefits of thymalfasin being investigated? Potential benefits being studied include improved immune function, reduced infection rates, enhanced response to vaccines, tumor regression, and improved survival outcomes in various diseases. Specific endpoints vary by trial but often include measures of immune cell activity, disease progression, and overall survival.
  • Are there any known side effects of thymalfasin? Based on previous clinical experience, thymalfasin appears to be generally well-tolerated. The most common reported side effects include mild injection site reactions and flu-like symptoms. However, the ongoing trials continue to monitor for any adverse events to further evaluate its safety profile.

Ongoing Clinical Trials on Thymalfasin

  • Study on Thymalfasin for Adults with Cystic Fibrosis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Thymalfasin: A synthetic 28-amino acid peptide identical to natural thymosin alpha 1, which acts as a biological response modifier to activate various cells of the immune system.
  • Abscopal effect: An immune-mediated tumor response observed in areas outside the radiation field when radiotherapy is delivered to a specific tumor site.
  • CD4+ T cells: A type of white blood cell that plays a crucial role in the immune system, particularly in coordinating the body's immune response to infections.
  • Lymphocytopenia: An abnormally low level of lymphocytes (a type of white blood cell) in the blood, which can impair the body's ability to fight infections.
  • Neoadjuvant therapy: Treatment given before the main treatment, typically to shrink a tumor before surgery or radiation therapy.
  • PD-1 inhibitor: A type of immunotherapy drug that blocks the PD-1 protein on T cells, potentially enhancing the immune system's ability to attack cancer cells.
  • Pathologic complete response (pCR): The absence of all detectable cancer in tissue samples removed during surgery, following neoadjuvant therapy.
  • Sepsis: A life-threatening condition that occurs when the body's response to infection causes widespread inflammation and organ dysfunction.
  • mHLA-DR: Monocyte Human Leukocyte Antigen DR, a marker of immune function often measured to assess the immune status of patients with sepsis.
  • SOFA score: Sequential Organ Failure Assessment score, used to track a patient's status during their stay in an intensive care unit to determine the extent of organ dysfunction.

References

  1. https://clinicaltrials.gov/study/NCT04428008
  2. https://clinicaltrials.gov/study/NCT04487444
  3. https://clinicaltrials.gov/study/NCT04963712
  4. https://clinicaltrials.gov/study/NCT02542137
  5. https://clinicaltrials.gov/study/NCT02542930
  6. https://clinicaltrials.gov/study/NCT02535988
  7. https://clinicaltrials.gov/study/NCT05086614
  8. https://clinicaltrials.gov/study/NCT02883595
  9. https://clinicaltrials.gov/study/NCT02867267